A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Burkert Pieske, MD
Charité University Medicine and German Heart Center
Principal Investigator - Christopher M. O'Connor, MD
Inova Heart and Vascular Institute
Principal Investigator - Mahesh J. Patel, MD
Merck Sharp & Dohme LLC
Study Director - Paul W. Armstrong, MD
Canadian VIGOUR Centre - University of Alberta
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Sept 2016
- Primary completion
- 18 Jun 2019
- Completion
- 2 Sept 2019
- Last update posted
- 15 Nov 2021
- Registered enrollment
- 5,050
- Registry id
- NCT02861534
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.